(HOWL) Werewolf Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US95075A1079
HOWL: Cancer, Immunotherapy, Interleukin, Molecules
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is a biopharmaceutical company specializing in the development of innovative cancer treatments that leverage the bodys immune system. Through its proprietary PREDATOR platform, the company designs conditionally activated molecules engineered to overcome the limitations of conventional proinflammatory immune therapies. These molecules are designed to stimulate both adaptive and innate immunity, offering a more targeted approach to cancer treatment. The companys lead product candidate, WTX-124, is a conditionally activated Interleukin-2 (IL-2) INDUKINE molecule currently in Phase I/Ib clinical trials for the treatment of advanced or metastatic solid tumors. WTX-330, another key candidate, is a conditionally activated Interleukin-12 (IL-12) INDUKINE molecule in Phase I clinical trials for advanced or metastatic solid tumors and lymphoma. Additionally, Werewolf Therapeutics is developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for cancer treatment, as well as WTX-712 (activated IL-21) and WTX-518 (activated IL-18) INDUKINE molecules for cancer. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Ticker Symbol: HOWL Exchange: NASDAQ Type: Common Stock Country Origin: United States GICS Sub Industry: Biotechnology
3-Month Forecast (Using Technical and Fundamental Data): Based on the technical data, HOWL is currently trading below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The stocks average trading volume over 20 days is 280,758 shares, with a last price of $1.24. The SMA 20, SMA 50, and SMA 200 are $1.35, $1.41, and $2.23, respectively, suggesting resistance levels above the current price. The ATR of $0.11 indicates low volatility. From a fundamental perspective, Werewolf Therapeutics has a market cap of $50.80M, with a price-to-book (P/B) ratio of 0.62, indicating potential undervaluation. However, the negative return on equity (RoE) of -69.50% and a high price-to-sales (P/S) ratio of 15.00 signal significant risks and operational challenges. In the next 3 months, HOWL is expected to face resistance near $1.35 and $1.41, with potential downside risks due to the negative earnings and high P/S ratio. However, any positive developments in its clinical trials could act as a catalyst for price movement. The stock is likely to remain range-bound between $1.00 and $1.50, barring any material news.
Additional Sources for HOWL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HOWL Stock Overview
Market Cap in USD | 40m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2021-04-30 |
HOWL Stock Ratings
Growth Rating | -79.6 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -81.9 |
Analysts | 4.67/5 |
Fair Price Momentum | 0.62 USD |
Fair Price DCF | - |
HOWL Dividends
No Dividends PaidHOWL Growth Ratios
Growth Correlation 3m | -85.9% |
Growth Correlation 12m | -93.2% |
Growth Correlation 5y | -77.1% |
CAGR 5y | -51.54% |
CAGR/Max DD 5y | -0.53 |
Sharpe Ratio 12m | -2.25 |
Alpha | -100.67 |
Beta | 1.915 |
Volatility | 83.81% |
Current Volume | 172.4k |
Average Volume 20d | 186.6k |
As of May 09, 2025, the stock is trading at USD 0.87 with a total of 172,422 shares traded.
Over the past week, the price has changed by -0.10%, over one month by +38.07%, over three months by -34.59% and over the past year by -84.12%.
No, based on ValueRay Analyses, Werewolf Therapeutics (NASDAQ:HOWL) is currently (May 2025) a stock to sell. It has a ValueRay Growth Rating of -79.58 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HOWL as of May 2025 is 0.62. This means that HOWL is currently overvalued and has a potential downside of -28.74%.
Werewolf Therapeutics has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy HOWL.
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, HOWL Werewolf Therapeutics will be worth about 0.7 in May 2026. The stock is currently trading at 0.87. This means that the stock has a potential downside of -21.84%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 10.2 | 1069% |
Analysts Target Price | 10.2 | 1069% |
ValueRay Target Price | 0.7 | -21.8% |